Dynavax Technologies Corp (DVAX) 16.96 $DVAX
Dance Biopharm Appoints Dr. Tyler Martin to the Position of President and Director
PR Newswire - Wed Feb 11, 8:00AM CST
Dance Biopharm Inc. (Dance), a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced the appointment of J. Tyler Martin, M.D., to the newly created position of president. Dr. Martin has also been appointed to the board of directors. He brings more than 20 years of experience in the biotechnology industry to Dance, where he oversees company operations, reporting to Dr. John Patton, CEO.
DVAX: 16.96 (+0.66)
Dynavax Announces Laura Brege Has Joined Board of Directors and Denise Gilbert Will Retire
Marketwired - Fri Feb 06, 8:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee.
DVAX: 16.96 (+0.66), RRD-P.VN: 0.010 (+0.005), ACAD: 34.21 (+0.37), PETX: 16.52 (-0.10)
Pancreatitis Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Wed Jan 21, 4:31AM CST
The report "Pancreatitis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Pancreatitis. Pancreatitis simply means inflammation of the pancreas. Pancreatic damage happens when the digestive enzymes are activated before they are released into the small intestine and begin attacking the pancreas. Acute pancreatitis is a sudden inflammation that lasts for a short time. Chronic pancreatitis is long-lasting inflammation of the pancreas. It most often happens after an episode of acute pancreatitis. The most common symptoms of pancreatitis are severe upper abdominal or left upper quadrant burning pain radiating to the back, nausea and vomiting that is worsened with eating. Complete Report is Available @ http://www.rnrmarketresearch.com/pancreatitis...eport.html .
DVAX: 16.96 (+0.66), GSK: 47.94 (+1.99)
Dynavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Marketwired - Mon Jan 12, 3:05PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2015 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
DVAX: 16.96 (+0.66), JPM: 59.67 (+0.10)
My Predictions For 2015 - Final Chapter
Bret Jensen - at Seeking Alpha - Mon Jan 12, 8:07AM CST
DVAX: 16.96 (+0.66), AGEN: 5.03 (-0.01), GILD: 101.90 (+1.10), GBX: 57.22 (-0.59), AAPL: 127.08 (+0.62)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 90.70 (+0.93), DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04), NVAX: 8.80 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CLDN: 16.45 (-0.05), GSK: 47.94 (+1.99)
OTC Daily Alert Stock Watch - Dynavax, (Nasdaq: DVAX)
WorldStockWire - Mon Dec 29, 3:00PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DVAX: 16.96 (+0.66)
Dynavax secures funding
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:20AM CST
DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04)
Dynavax Secures $40 Million Credit Facility With Hercules Technology Growth Capital
Marketwired - Mon Dec 29, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) for up to $40 million of total funding. Dynavax drew the first tranche of $10 million on closing and has access to an additional $30 million in 2015, at Dynavax's option, if it achieves certain milestones relating to the ongoing Phase 3 study of HEPLISAV-B(TM) (HBV-23).
DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), IMMU: 3.84 (unch), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ARGS: 8.35 (-0.12), NVO: 43.76 (+0.61), IDRA: 4.10 (-0.14), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), CBMG: 24.32 (-1.17), CELGZ: 3.17 (-0.04)
DynaVax Technologies: The Small Cap Gem Focus Stock Of The Week
Bret Jensen - at Seeking Alpha - Wed Dec 10, 2:02PM CST
DVAX: 16.96 (+0.66)
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 5:20PM CST
Dynavax Technologies Corp. (DVAX) announced that the company has amended its existing research and license agreement with AstraZeneca plc (AZN).
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Dynavax to advance TLR9 Agonist into Phase 2a asthama clinical study in partnership with AstraZeneca
M2 - Tue Dec 09, 6:28AM CST
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) stated on Monday that it will fully conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma under an amendment to the existing Research Collaboration and License Agreement with AstraZeneca.
DVAX: 16.96 (+0.66)
Dynavax Announces Webcast of R&D Day
Marketwired - Tue Dec 09, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Thursday, December 11, 2014 in New York City. This event for institutional investors will focus on Dynavax's leadership in the application of toll-like receptor (TLR) biology, including updates on its Phase 3 investigational adult hepatitis B vaccine, HEPLISAV-B(TM), clinical programs in cancer and asthma, and advancing preclinical candidates. The webcast of the presentations and Q&A will begin at 8:30 a.m. ET and is scheduled to conclude at 11:00 a.m. ET.
DVAX: 16.96 (+0.66)
Dynavax to initiate asthma trial
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 9:55AM CST
DVAX: 16.96 (+0.66), AZN: 69.96 (+0.20)
Global Ragweed Allergy Clinical Trials Review, H2, 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/g87gqk/ragweed_allergy) has announced the addition of the "Ragweed Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Ragweed Allergy Global Clinical Trials Review, H2, 2014" provides data on the Ragweed Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ragweed Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ragweed Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Circassia Pharmaceuticals plc - Dynavax Technologies Corporation - Merck & Co., Inc. - ALK-Abello A/S - UCB S.A. - Greer Laboratories, Inc. - Curalogic A/S (Inactive) - Biothera, Inc. - Antigen Laboratories - Anergis SA Clinical Trial Overview of Top Institutes / Government - Azienda Ospedaliera L. Sacco - Mahidol University - The National Institute of Allergy and Infectious Diseases - University of Chicago - Rambam Health Care Campus For more information visit http://www.researchandmarkets.com/research/g8...ed_allergy
DVAX: 16.96 (+0.66), MRK: 58.81 (-0.07)
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study
Marketwired - Mon Dec 08, 5:00AM CST
Dynavax Technologies Corp. (NASDAQ: DVAX) today announced that the Company and AstraZeneca AB ("AstraZeneca"
signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma.
DVAX: 16.96 (+0.66)
Global Hepatitis B Clinical Trials Market Review H2 2014 Report at ReportsnReports.com
PRWeb - Wed Dec 03, 2:38AM CST
The clinical trial report "Hepatitis B Global Clinical Trials Review H2 2014" provides data on the Hepatitis B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis B. Complete Report on Aspergillosis Clinical Trials Review Report Available @ http://www.reportsnreports.com/reports/319731...-2014.html .
DVAX: 16.96 (+0.66), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
Dynavax Regains TLR 7/9 Inhibitor DV1179 Rights from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 4:20PM CST
Dynavax (DVAX) regained full rights to the development of its experimental therapeutic candidate, DV1179, following the expiration of its collaboration agreement with GlaxoSmithKline.
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 16.96 (+0.66), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), ASMB: 10.46 (+0.46), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
Dance Biopharm Appoints Dr. Tyler Martin to the Position of President and Director
PR Newswire - Wed Feb 11, 8:00AM CST
Dance Biopharm Inc. (Dance), a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced the appointment of J. Tyler Martin, M.D., to the newly created position of president. Dr. Martin has also been appointed to the board of directors. He brings more than 20 years of experience in the biotechnology industry to Dance, where he oversees company operations, reporting to Dr. John Patton, CEO.
DVAX: 16.96 (+0.66)
Dynavax Announces Laura Brege Has Joined Board of Directors and Denise Gilbert Will Retire
Marketwired - Fri Feb 06, 8:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Laura Brege to its Board of Directors and Audit Committee. Denise Gilbert, a director and the Chair of the Audit Committee since 2004, will retire from her positions with the company following the next Audit Committee meeting, whereupon Ms. Brege will become Chair of the Committee.
DVAX: 16.96 (+0.66), RRD-P.VN: 0.010 (+0.005), ACAD: 34.21 (+0.37), PETX: 16.52 (-0.10)
Pancreatitis Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Wed Jan 21, 4:31AM CST
The report "Pancreatitis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Pancreatitis. Pancreatitis simply means inflammation of the pancreas. Pancreatic damage happens when the digestive enzymes are activated before they are released into the small intestine and begin attacking the pancreas. Acute pancreatitis is a sudden inflammation that lasts for a short time. Chronic pancreatitis is long-lasting inflammation of the pancreas. It most often happens after an episode of acute pancreatitis. The most common symptoms of pancreatitis are severe upper abdominal or left upper quadrant burning pain radiating to the back, nausea and vomiting that is worsened with eating. Complete Report is Available @ http://www.rnrmarketresearch.com/pancreatitis...eport.html .
DVAX: 16.96 (+0.66), GSK: 47.94 (+1.99)
Dynavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Marketwired - Mon Jan 12, 3:05PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2015 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
DVAX: 16.96 (+0.66), JPM: 59.67 (+0.10)
My Predictions For 2015 - Final Chapter
Bret Jensen - at Seeking Alpha - Mon Jan 12, 8:07AM CST
DVAX: 16.96 (+0.66), AGEN: 5.03 (-0.01), GILD: 101.90 (+1.10), GBX: 57.22 (-0.59), AAPL: 127.08 (+0.62)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 90.70 (+0.93), DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04), NVAX: 8.80 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CLDN: 16.45 (-0.05), GSK: 47.94 (+1.99)
OTC Daily Alert Stock Watch - Dynavax, (Nasdaq: DVAX)
WorldStockWire - Mon Dec 29, 3:00PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DVAX: 16.96 (+0.66)
Dynavax secures funding
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:20AM CST
DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04)
Dynavax Secures $40 Million Credit Facility With Hercules Technology Growth Capital
Marketwired - Mon Dec 29, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) for up to $40 million of total funding. Dynavax drew the first tranche of $10 million on closing and has access to an additional $30 million in 2015, at Dynavax's option, if it achieves certain milestones relating to the ongoing Phase 3 study of HEPLISAV-B(TM) (HBV-23).
DVAX: 16.96 (+0.66), HTGC: 15.49 (+0.04)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), IMMU: 3.84 (unch), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ARGS: 8.35 (-0.12), NVO: 43.76 (+0.61), IDRA: 4.10 (-0.14), ANTH: 3.84 (+0.06), MRK: 58.81 (-0.07), CBMG: 24.32 (-1.17), CELGZ: 3.17 (-0.04)
DynaVax Technologies: The Small Cap Gem Focus Stock Of The Week
Bret Jensen - at Seeking Alpha - Wed Dec 10, 2:02PM CST
DVAX: 16.96 (+0.66)
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 5:20PM CST
Dynavax Technologies Corp. (DVAX) announced that the company has amended its existing research and license agreement with AstraZeneca plc (AZN).
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Dynavax to advance TLR9 Agonist into Phase 2a asthama clinical study in partnership with AstraZeneca
M2 - Tue Dec 09, 6:28AM CST
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) stated on Monday that it will fully conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma under an amendment to the existing Research Collaboration and License Agreement with AstraZeneca. DVAX: 16.96 (+0.66)
Dynavax Announces Webcast of R&D Day
Marketwired - Tue Dec 09, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Thursday, December 11, 2014 in New York City. This event for institutional investors will focus on Dynavax's leadership in the application of toll-like receptor (TLR) biology, including updates on its Phase 3 investigational adult hepatitis B vaccine, HEPLISAV-B(TM), clinical programs in cancer and asthma, and advancing preclinical candidates. The webcast of the presentations and Q&A will begin at 8:30 a.m. ET and is scheduled to conclude at 11:00 a.m. ET.
DVAX: 16.96 (+0.66)
Dynavax to initiate asthma trial
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 9:55AM CST
DVAX: 16.96 (+0.66), AZN: 69.96 (+0.20)
Global Ragweed Allergy Clinical Trials Review, H2, 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/g87gqk/ragweed_allergy) has announced the addition of the "Ragweed Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Ragweed Allergy Global Clinical Trials Review, H2, 2014" provides data on the Ragweed Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ragweed Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ragweed Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Circassia Pharmaceuticals plc - Dynavax Technologies Corporation - Merck & Co., Inc. - ALK-Abello A/S - UCB S.A. - Greer Laboratories, Inc. - Curalogic A/S (Inactive) - Biothera, Inc. - Antigen Laboratories - Anergis SA Clinical Trial Overview of Top Institutes / Government - Azienda Ospedaliera L. Sacco - Mahidol University - The National Institute of Allergy and Infectious Diseases - University of Chicago - Rambam Health Care Campus For more information visit http://www.researchandmarkets.com/research/g8...ed_allergy
DVAX: 16.96 (+0.66), MRK: 58.81 (-0.07)
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study
Marketwired - Mon Dec 08, 5:00AM CST
Dynavax Technologies Corp. (NASDAQ: DVAX) today announced that the Company and AstraZeneca AB ("AstraZeneca"
signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma. DVAX: 16.96 (+0.66)
Global Hepatitis B Clinical Trials Market Review H2 2014 Report at ReportsnReports.com
PRWeb - Wed Dec 03, 2:38AM CST
The clinical trial report "Hepatitis B Global Clinical Trials Review H2 2014" provides data on the Hepatitis B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis B. Complete Report on Aspergillosis Clinical Trials Review Report Available @ http://www.reportsnreports.com/reports/319731...-2014.html .
DVAX: 16.96 (+0.66), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
Dynavax Regains TLR 7/9 Inhibitor DV1179 Rights from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 4:20PM CST
Dynavax (DVAX) regained full rights to the development of its experimental therapeutic candidate, DV1179, following the expiration of its collaboration agreement with GlaxoSmithKline.
DVAX: 16.96 (+0.66), BIIB: 391.66 (-0.45), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 16.96 (+0.66), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), ASMB: 10.46 (+0.46), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
